NMPA (China) approves ensartinib to treat first line ALK positive NSCLC.
Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company announced that Xcovery’s affiliate Betta Pharmaceuticals has received the National Medical Products Administration (NMPA)’s approval of ensartinib, as Ensacove, in China for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).
Ensartinib has been previously approved for the second-line treatment of ALK-positive NSCLC in China in 2020.
Ensartinib is a next generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals. NMPA’s approval in China marked the first ensartinib approval based on the results of the eXalt3 study, an Xcovery sponsored randomized global phase III study, designed to evaluate the efficacy and safety of ensartinib in the first-line treatment of ALK-positive NSCLC. Results of the eXalt3 were published in JAMA Oncology in September 2021.
150 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.